What STEP-1 Extension Actually Changes in Clinical Practice

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for What STEP-1 Extension Actually Changes in Clinical Practice

At a glance

| Field | Detail | |---|---| | Trial | STEP-1 Extension | | N | 327 (of 803 original STEP-1 completers) | | Intervention | Semaglutide 2.4 mg SC weekly (68 weeks, then discontinued) | | Comparator | Placebo (continued through extension) | | Extension Duration | 52 weeks (weeks 68 to 120) | | Primary Endpoint | Percent change in body weight at week 120 vs. baseline | | Key Result | Mean weight regain of 11.6 percentage points from week 68 to 120; net loss from baseline only 5.6% at week 120 vs. 17.3% at week 68 |

Why the Abstract Does Not Tell the Full Story

The headline, "two-thirds of weight regained," travels well on social media. The methodology behind it is more informative than the headline, and the implications for practice are more specific than most summaries suggest.

The STEP-1 Extension was a post-treatment observational withdrawal period appended to the original STEP-1 randomized controlled trial, which ran 68 weeks and enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity (but without diabetes). After week 68, participants who had completed treatment were invited to enter an additional 52-week off-treatment follow-up. Of 803 completers, 327 agreed to continue being observed: 184 from the semaglutide arm and 143 from the placebo arm. No additional drug was administered. Participants resumed standard-of-care lifestyle support only.

This design matters clinically. The extension was not a randomized withdrawal trial. Participants who agreed to continue observation may differ systematically from those who declined. People who regained weight rapidly and felt the experience was distressing might have been less likely to remain in follow-up, which would bias the reported 11.6 percentage-point regain toward underestimation. The Wilding et al. publication acknowledges this directly as a limitation.

The 52-week gap between last dose and final observation is also clinically meaningful. Semaglutide's half-life is approximately five weeks, meaning drug concentrations were negligible by week 78 or so. Weight regain plotted by time showed a steep initial trajectory: the majority of regained weight accumulated in the first 20 weeks after discontinuation, then decelerated. This kinetic pattern is consistent with the drug's mechanism. Semaglutide suppresses appetite and slows gastric emptying through GLP-1 receptor agonism, and once those central and peripheral signals disappear, caloric intake tends to return toward pre-treatment levels unless durable behavioral changes have occurred. The FDA prescribing information for semaglutide 2.4 mg (Wegovy) does not specify a treatment duration, but the mechanism-of-action section makes clear the drug's effects are pharmacodynamically active and not disease-modifying in a persistent sense.

The Cardiometabolic Reversal Data

Weight is the primary endpoint, but the cardiometabolic secondary data deserve at least equal attention in clinical practice. From Wilding et al. 2022, the changes at week 120 compared with week 68 in the semaglutide group included:

| Parameter | Week 68 (end of treatment) | Week 120 (1 year post-stop) | Change | |---|---|---|---| | Body weight | -17.3% from baseline | -5.6% from baseline | +11.6 pp regain | | Waist circumference | -13.7 cm | -5.6 cm | +8.1 cm reversal | | Systolic BP | -6.2 mmHg | -2.4 mmHg | +3.8 mmHg reversal | | HbA1c | -0.45% | -0.23% | Partial reversal | | Fasting glucose | Improved | Partially reversed | Partial reversal | | HDL cholesterol | Improved | Largely reversed | Near-full reversal |

These reversals are not trivial. A 3.8 mmHg return in systolic blood pressure represents meaningful cardiovascular risk reconstitution, especially in patients who were enrolled in STEP-1 specifically because they had weight-related comorbidities. Clinicians framing the conversation as "you can take this for a year, then we reassess" need to have a specific plan for what happens to these parameters during that reassessment window.

What the Trial Population Limits You in Applying

The STEP-1 population was adults with BMI ≥30, or ≥27 with a qualifying comorbidity, but explicitly excluding type 2 diabetes. The trial therefore says nothing about discontinuation dynamics in patients with diabetes, who represent a large fraction of clinical prescribing. STEP-2, which studied semaglutide 2.4 mg in adults with type 2 diabetes, showed smaller absolute weight loss during treatment (9.6% vs. 14.9% in STEP-1), suggesting that the regain fraction after discontinuation could behave differently in that subgroup, though no diabetes-specific withdrawal extension has been published as of this writing.

The extension cohort was also predominantly white and female. Of the 327 participants, approximately 74% were women and roughly 84% were white. Obesity prevalence, adipose tissue distribution, and possibly GLP-1 receptor sensitivity vary by sex and ancestry. Applying the 11.6 percentage-point regain estimate uniformly across a diverse clinic population oversimplifies the underlying heterogeneity. The Obesity Medicine Association's 2023 clinical practice statement cautions specifically against treating published weight-loss trials as universally representative and calls for individualized treatment planning that accounts for demographic and comorbidity differences.

Which Guidelines Have Actually Shifted

The American Gastroenterological Association published its 2022 clinical practice guideline on obesity pharmacotherapy, which explicitly cited the chronic-disease model of obesity as the rationale for recommending long-term medication continuation over episodic prescribing. The AGA guidance references STEP-1 and the extension data as supporting evidence that discontinuation leads to rapid clinical deterioration.

The American Diabetes Association Standards of Medical Care in Diabetes, 2024 similarly moved away from time-limited framing, recommending that GLP-1 receptor agonist therapy be continued as long as it is effective and tolerated, with shared decision-making rather than automatic cessation at an arbitrary endpoint.

The Endocrine Society's obesity guidelines, last substantively revised before the STEP-1 Extension was published, are currently under update. Drafts circulating in 2023 have adopted language consistent with indefinite treatment for pharmacologically responsive patients, language that was not present in prior versions.

What has NOT changed, despite the data: insurance authorization windows. Most US payers still require prior authorization for semaglutide 2.4 mg, and many approve it for limited periods requiring re-authorization. The clinical implications of the STEP-1 Extension are therefore partly blocked by coverage architecture that has not kept pace with the evidence base. A clinician who understands the trial is still operating inside a system that may force discontinuation for non-clinical reasons, which is exactly the scenario the Wilding et al. extension paper describes producing harm.

Prescribing Pattern Shifts Worth Naming Specifically

Several specific changes in prescribing behavior are traceable to this trial and the discussion it generated:

Framing the initiation conversation differently. Before the extension data, some prescribers framed semaglutide as a weight-loss tool for a defined period. The extension data make a stronger case for framing initiation as the start of ongoing management, analogous to starting a statin, rather than as a course of treatment.

Earlier co-investment in behavioral infrastructure. If the drug will eventually be discontinued (by choice, cost, or coverage loss), the extension data suggest that behavioral modification needs to be more intensive during the active treatment period, not treated as an add-on. The STEP-1 original trial included reduced-calorie dietary counseling and exercise guidance for all participants. The degree to which that support was internalized and continued after drug cessation was not captured, which is itself a design limitation with direct clinical relevance.

Contingency planning at initiation. Some obesity medicine specialists now recommend documenting a discontinuation plan at the time of prescribing, covering what monitoring will occur, what weight threshold will trigger re-evaluation, and what alternatives exist if coverage lapses. This is practice change driven directly by knowing what the extension data showed.

Higher threshold for elective discontinuation. Patients who achieve strong responses and then want to stop the drug "to see if I can maintain it on my own" are now counseled with specific data about expected regain timeline rather than general reassurance.

The Chronic-Disease Framing: Useful and Incomplete

The STEP-1 Extension is frequently cited as proof that obesity is a chronic disease requiring chronic treatment. That framing is clinically useful because it reduces stigma, aligns obesity management with how clinicians approach hypertension or dyslipidemia, and gives prescribers a principled reason to maintain therapy long-term.

The framing is also incomplete in ways clinicians should hold onto. A patient who loses 17% of body weight and then regains 12 percentage points has still retained a net 5.6% loss at one year off drug. For some patients, that residual loss is clinically meaningful. The extension data do not show a full return to baseline for most participants in the 52-week observation window, even though the trajectory was still ascending at week 120. Longer follow-up data are needed to know whether regain eventually plateaus or continues until full baseline weight is restored.

The SELECT trial, published in 2023, adds a separate dimension: semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, independent of weight loss alone. If the cardiovascular benefit is partly weight-independent (through anti-inflammatory or direct vascular mechanisms), then the argument for chronic therapy becomes even stronger for high-risk patients, because discontinuation removes both the weight benefit and potentially a direct cardioprotective effect simultaneously.

Limitations the Authors Named and What They Mean Practically

The Wilding et al. paper lists several limitations worth translating into clinical terms:

  • Observation-only design after week 68. No randomization occurred in the extension, meaning selection bias is possible. Patients who remained in follow-up may not represent those who stopped and did not consent to observation.
  • No active intervention in the extension. The extension shows what happens with lifestyle support alone after discontinuation. It does not test re-treatment, dose reduction, or transition to an alternative agent.
  • Relatively short post-discontinuation follow-up. One year may not be enough to see where weight stabilizes. Patients and clinicians cannot know from this trial alone whether regain plateaus or continues beyond week 120.
  • No diabetes subgroup. As noted above, the population excludes a large real-world prescribing group.
  • No biomarker or genetic moderators reported. Which patients regain fastest, and which retain more of the loss, is not disaggregated in the published data.

Frequently asked questions

›What percentage of weight loss returned after stopping semaglutide in STEP-1 Extension?
›Does stopping semaglutide also reverse cardiovascular risk improvements?
›How quickly does weight regain happen after stopping semaglutide?
›Does the STEP-1 Extension apply to patients with type 2 diabetes?
›Have major clinical guidelines changed because of this trial?
›What should a clinician tell a patient who wants to stop semaglutide to see if they can maintain weight on their own?
›Is the STEP-1 Extension a randomized trial?
›Does any trial test re-starting semaglutide after a gap?
›What does the STEP-1 Extension imply for patients who cannot afford continuous therapy?
›Does a lower starting BMI predict less regain after stopping?

References

  1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33667417/
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/38092905/
  5. Yoo JS, et al. American Gastroenterological Association clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. https://pubmed.ncbi.nlm.nih.gov/35227530/
  6. American Diabetes Association. Standards of Medical Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1). https://pubmed.ncbi.nlm.nih.gov/38078589/
  7. Obesity Medicine Association clinical practice statement 2023. https://pubmed.ncbi.nlm.nih.gov/37302408/
  8. Semaglutide injection 2.4 mg (Wegovy) FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf